Triamcinolone acetonide-moxifloxacin controls inflammation after cataract surgery
An injection of triamcinolone acetonide-moxifloxacin controlled intraocular inflammation and corneal edema after cataract surgery.
The retrospective longitudinal comparative study included 681 eyes (group 1) that received Tri-Moxi (triamcinolone acetonide-moxifloxacin, Imprimis Pharmaceuticals) and an NSAID after undergoing cataract surgery. This group was compared with 514 eyes (group 2) that received a standard eye drop therapy of antibiotic, corticosteroid and NSAID after cataract surgery.
Researchers evaluated postoperative inflammation, corneal edema and the rate of high IOP between the two groups.
Anterior chamber cell reaction severity in group 1 decreased by 34% at 1 week postoperative and 35.7% at 1 month postoperative compared with group 2 (P = .001 and P = .02, respectively).
Group 2 had a lower degree of corneal edema on postoperative day 1 (P = .001), but there was no significant difference in corneal edema severity between the two groups at later follow-up visits.
Rate of high IOP was not significantly different between the groups during any postoperative timepoints.
“Triamcinolone acetonide-moxifloxacin injection can be considered as a promising substitute
for standard eye drop therapy, especially in patients who have poor compliance with eye drop use,” the study authors wrote. – by Robert Linnehan
Disclosures: The authors report no relevant financial disclosures.